<h1>Company pivots to MedTech, diagnostics and genomics raise regulatory, data protection, IP and cross-border compliance risks</h1> A senior company executive received consecutive features in an international business magazine, highlighting the company's strategic shift to MedTech, diagnostics, genomics and biotech manufacturing and its flagship products including dialysis, genomic testing and AI diagnostic tools. The company reports US FDA registration and planned geographic expansion and investments, elevating regulatory, compliance and market-entry considerations across jurisdictions. Potential legal issues include regulatory compliance for medical devices and diagnostics, cross-border regulatory approvals, data protection for genomic/AI products, IP protection and licensing, supply-chain and manufacturing compliance, and disclosure obligations to investors and regulators.